Enliven Therapeutics, Inc. $ELVN Shares Purchased by Baker BROS. Advisors LP

Baker BROS. Advisors LP grew its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 136.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 271,406 shares of the company’s stock after purchasing an additional 156,573 shares during the quarter. Baker BROS. Advisors LP’s holdings in Enliven Therapeutics were worth $4,180,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. Swiss National Bank lifted its stake in shares of Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after purchasing an additional 1,100 shares in the last quarter. Finally, Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $44.86 on Thursday. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $48.53. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of -26.86 and a beta of 0.29. The stock’s 50-day simple moving average is $41.73 and its 200-day simple moving average is $31.24.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, research analysts predict that Enliven Therapeutics, Inc. will post -1.71 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Monday, April 20th. Guggenheim assumed coverage on Enliven Therapeutics in a research note on Tuesday, May 12th. They set a “buy” rating and a $80.00 price objective on the stock. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright boosted their price objective on Enliven Therapeutics from $48.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $63.40.

Insiders Place Their Bets

In related news, Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares of the company’s stock, valued at $1,792,073.36. The trade was a 16.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by corporate insiders.

Enliven Therapeutics Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.